Table 1.
Demographics of randomized and treated subjects
Characteristic | Included in microbiome analyses
|
* p value | All ABC (n=247a) | ||
---|---|---|---|---|---|
Yes (n=155) | No (n=92) | ||||
Age at randomization (years) | Mean (SD) | 57.7 (11.3) | 58.4 (11.2) | 0.63 | 57.9 (11.3) |
Hispanic or Latina: n (%) | 33 (21) | 11 (12) | 0.06 | 44 (18) | |
Race: n (%) | White | 113 (73) | 81 (88) | 0.01 | 194 (79) |
Black/African American | 30 (19) | 11 (12) | 41 (17) | ||
Other | 12 (8) | 0 | 12 (5 | ||
BMI | Mean (SD) | 32.9 (7.7) | 31.8 (7.5) | 0.29 | 32.5 (7.6) |
Maritalstatus: n (%) | Married/living as married | 69 (45) | 46 (50) | 0.79 | 115 (47) |
Divorced/separated/widowed | 59 (38) | 33 (36) | 92 (37) | ||
Other | 1 (1) | 0 | 1 (0 | ||
Single, never married | 20 (13) | 11 (12) | 31 (13) | ||
Some college or greater: n (%) | 112 (72) | 64 (70) | 0.44 | 176 (71) | |
Health insurance: n (%) | Private only | 75 (48) | 46 (50) | 0.49 | 121 (49) |
Medicare or Medicaid only | 13 (8) | 13 (14) | 26 (11) | ||
Other only | 40 (26) | 22 (24) | 62 (25) | ||
Combination of types | 26 (17) | 11 (12) | 37 (15) | ||
Not reported | 1 (1) | 0 | 1 (0 ) | ||
Smoking: n (%) | Never | 84 (54) | 56 (61) | 0.03 | 140 (57) |
Previous | 58 (37) | 21 (23) | 79 (32) | ||
Current | 13 (8) | 14 (15) | 27 (11) | ||
Menopause: n (%) | Pre-menopausal | 23 (15) | 14 (15) | 0.85 | 37 (15) |
Post-menopausal | 123 (79) | 71 (77) | 194 (79) | ||
Not sure | 9 (6) | 7 (8) | 16 (6) | ||
No prior anticholinergic exposure: n (%) | 68 (44) | 34 (37) | 0.29 | 102 (41) | |
3-day diary total IE/day | Mean (SD) | 6.1 (3.3) | 5.7 (3.0) | 0.38 | 6.0 (3.2) |
3-day diary urge IE/day | Mean (SD) | 5.1 (2.8) | 4.8 (2.5) | 0.44 | 5.0 (2.7) |
Baseline PVR (mL) | Mean (SD) | 34.3 (46.7) | 38.8 (44.8) | 0.47 | 36.0 (46.0) |
IE incontinent episodes, PVR postvoid residual urine, ABC Anticholinergic Versus Botulinum Toxin A Comparison Trial
p value based on the linear regression model with the treatment group as the explanatory value for continuous variables and Chi-squared tests for categorical measures
Of the 249 randomized individuals, 2 withdrew prior to treatment and did not provide baseline data